Merck & Co., Inc. Hits New 52-Week High at USD 125.11

Merck & Co., Inc. has reached a significant milestone by hitting a new 52-week high of USD 125.11 on February 25, 2026. This achievement highlights the stock's notable activity within the Pharmaceuticals & Biotechnology sector, where Merck operates as a large-cap company with a market capitalization of USD 432,043 million. Despite the recent high, the company's one-year performance reflects a decline of 6.87%, contrasting with the S&P 500's gain of 12.95% over the same period. Merck's price-to-earnings (P/E) ratio stands at 16.00, indicating its valuation relative to earnings. The company also offers a dividend yield of 3.85%, which may appeal to income-focused investors. With a debt-to-equity ratio of 0.45, Merck maintains a relatively low level of debt, contributing to its financial stability. However, the return on equity is currently at 0.00%, suggesting that the company is not generating profits relative to shareholder equity at this time. The stock's 52-week low was recorded at USD 73.31, marking a significant recovery to its current high.